MedPath

Clinical Performance Evaluation Study of the QuotientMosaiQ'M Treponema pallidum/CMV Screening Test-MosaiQ Serological Oisease Screening (SOS) Magazines EUStudy, Testing for Antibodies to Treponema pallidum andCytomegalovirus in Blood Oonors(EU; SDS MACH 1)

Conditions
Infectioues disease serology syphilis
B25
Cytomegaloviral disease
Registration Number
DRKS00017023
Lead Sponsor
Quotient Business Park Terre Bonne
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
4826
Inclusion Criteria

Not applicable – Performance Evaluation Study for a single use microarray for serological disease screening

Exclusion Criteria

Not applicable – Performance Evaluation Study for a single use microarray for serological disease screening

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare the MosaiQ Platform to CE marked instruments/assays currently on the market.<br>Instrument data will be entered into a central database using a printed copy of the instrument results - this will be the source document. Data will be entered on an excel spreadsheet - this will be the source document and subsequently entered into a central database. Site will be provided indepnedent laptops for data entry, and a USB sticks to remove data from the site and upload to the EDC system<br>The test results will be evaluated after finishing the tests.
Secondary Outcome Measures
NameTimeMethod
To evaluate the user performance of the microarray for each tested category on the MosaiQ Platform.
© Copyright 2025. All Rights Reserved by MedPath